Clinical Trials Directory

Trials / Completed

CompletedNCT04573894

Diagnostic Performance of Plasma Procalcitonin for the Detection of Blood Cultures Contaminations

Diagnostic Performance of Plasma Procalcitonin in Screening for Contamination When Detecting Potential Contaminants in Blood Cultures

Status
Completed
Phase
Study type
Observational
Enrollment
147 (actual)
Sponsor
Central Hospital, Nancy, France · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

In blood cultures, species considered as potentially contaminating (coagulase negative staphylococci (CNS), Bacillus spp., Corynebacterium spp., Cutibacterium acnes, Micrococcus spp., viridans group streptococci, and Clostridium perfringens) can, however, be responsable for true bacteremia. Blood levels of the prohormone procalcitonin (PCT) markedly increase in the early stages of bacterial infections. The aim of our study is to determine the role of plasma PCT as a biomarker differentiating blood culture contaminations from true bacteremia.

Detailed description

Blood culture contamination is defined by the introduction into of a microorganism into blood culture bottles from either the patient's or healthcare worker's flora, or the immediate environment during specimen collection. Species considered as potentially contaminating (coagulase negative staphylococci (CNS), Bacillus spp., Corynebacterium spp., Cutibacterium acnes, Micrococcus spp., viridans group streptococci, and Clostridium perfringens) can, however, be responsible for true bacteremia. If an organism belonging to one of those species is detected in isolates, rapidly and accurately assessing its contaminant or infectious potential is hence important to ensure effective antibiotic therapy as well as to reduce financial burden caused by unnecessary treatments, and additional clinical and laboratory costs. Blood levels of the prohormone procalcitonin (PCT) markedly increase in the early stages of bacterial infections. The aim of our study is to determine the role of plasma PCT as a biomarker differentiating blood culture contaminations from true bacteremia.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTProcalcitonin dosagePlasma PCT levels measured by automated enzyme immunoassay (Kryptor).

Timeline

Start date
2020-06-01
Primary completion
2020-07-31
Completion
2020-09-05
First posted
2020-10-05
Last updated
2020-10-05

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT04573894. Inclusion in this directory is not an endorsement.